Please assess the completion status of the following clinical trial:

Trial Title: The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Patent main portal vein with hepatopetal flow~* Bilirubin less than or equal to 2.5 mg/dl, albumin \>2.8g/dl, alkaline phosphatase \<630IU/L, AST \<235IU/L, ALT \<265IU/L, INR \<2.0, PTT \<40sec., absolute neutrophil count \>1K/cumm, platelet count \>100K/cumm~* No encephalopathy~* No previous biliary ductal intervention~* Child A status~* Confirmation of Hepatocellular Carcinoma (through biopsy or radiological exam)~* Unresectable HCC and ineligible for possible curative therapies~* Normal ECG with QT \<480 msec within the previous 2 months~* Normal MUGA scan within the previous 2 months~* Measureable disease per the Response Evaluation Criteria in Solid Tumors (RECIST)~* Subject is competent and willing to provide written informed consent in order to participate in the study~Exclusion Criteria:~* Thrombosis or hepatofugal flow in the main portal vein; presence of a large shunt which in the operator's opinion precludes embolization~* Replacement of greater than 50% of the liver parenchyma by tumor~* Bilirubin greater than or equal to 2.6 mg/dl~* ECOG performance status of 2 or greater~* Previous liver directed therapy~* Previous biliary intervention (excluding cholecystectomy)~* Allergy to iodinated contrast used for angiography~* Elevated creatinine greater than or equal to 1.8 mg/dl~* Women who are pregnant or nursing~* Patients in which any of the following are contraindicated: 1)the use of doxorubicin, 2)MRI or CT scans, 3) Hepatic embolization procedures~* Patients with active bacterial or fungal infection that is deemed to be clinically significant by the investigator~* Patients with cardiac disease, including congestive heart failure, recent myocardial infarction, or uncontrolled arrhythmias~* Non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- doxorubicin-eluting LC Bead (Type: EXPERIMENTAL): transarterial chemoembolization using doxorubicin-eluting LC Beads

Based on this trial design, predict the completion outcome and termination type (if applicable).